TIDMNSCI
NetScientific PLC
01 November 2018
NetScientific plc
("NetScientific" or the "Company" or the "Group")
Vortex Biosciences and STRATEC GmbH announce global partnership
to scale-up manufacturing for liquid biopsy platform
London, UK - 1 November 2018 - NetScientific plc
("NetScientific", AIM:NSCI), the transatlantic healthcare IP
commercialisation group, announces that its US-based portfolio
company, Vortex BioSciences, has entered into a global
manufacturing agreement with STRATEC Consumables GmbH ("STRATEC")
to produce a customised chip, a crucial component of Vortex's
automated liquid biopsy platform (VTX-1). STRATEC will also assist
Vortex with scale-up to commercialisation with a view to increasing
the product's prominence in the clinical space as a diagnostic and
monitoring tool.
Commenting on the news, Francois Martelet, Chairman of Vortex
BioSciences Inc. and CEO of NetScientific said: "Partnering with
STRATEC to manufacture the VTX-1 microfluidic chip will create a
reproducible process that will allow Vortex's technology to enter
the market and readily address demand as it surges. We look forward
to the results of this collaboration and foresee Vortex playing a
crucial role in establishing CTCs as part of the standard of care
in oncology treatment."
NetScientific holds 66.1% of Vortex Biosciences on a fully
diluted basis.
# # #
For more information, please contact:
NetScientific Tel: +44 (0)20 3514 1800
François R. Martelet,
M.D., CEO
Ian Postlethwaite, CFO
Consilium Strategic Communications Tel: +44 (0)20 3709 5700
Mary-Jane Elliott / Chris netscientific@consilium-comms.com
Welsh /
Laura Thornton
WHIreland (NOMAD and Broker)
Chris Fielding / Jessica Cave Tel: +44 (0)20 7220 1666
/
Chris Viggor bob@vortexbiosciences.com
Vortex Biosciences
Bob Englert, CEO
About NetScientific
NetScientific is a transatlantic healthcare technology group
with an investment strategy focused on sourcing, funding and
commercialising technologies that significantly improve the health
and well-being of people with chronic diseases. For more
information, please visit the website at www.netscientific.net
STRATEC Consumables and Vortex BioSciences Announce
Manufacturing Partnership
STRATEC Consumables and Vortex BioSciences enter into a supply
agreement for manufacturing a microfluidic chip for the VTX-1
Liquid Biopsy System.
Menlo Park, CA, USA and Salzburg, Austria - November 1, 2018 -
Vortex BioSciences, a NetScientific portfolio company and STRATEC
Consumables GmbH, a wholly owned subsidiary of STRATEC Biomedical
AG, Birkenfeld, Germany, announced the signing of a supply
agreement covering a customized microfluidic polymer chip. This
chip is a key component of the VTX-1 instrument, an automated
liquid biopsy platform which provides a simple, label free
isolation of circulating tumor cells directly from a tube of
blood.
This microfluidic research platform was developed in Dino Di
Carlo's Lab at UCLA which has been successfully transferred to the
commercial VTX-1 Liquid Biopsy System. The label-free microfluidic
device utilizes inertial lift and laminar microvortices, allowing
larger and more deformable cancer cells to be collected while
smaller cells such as red and white blood cells pass through. With
this technology, Vortex BioSciences is offering the best available
liquid biopsy platform for CTC isolation and collection from
patient samples.
Adapting the design to a commercial scale microfluidic device
can be guaranteed at STRATEC at their ISO-13485 certified facility
in Salzburg, Austria. By offering technical capabilities from
initial concept through mass manufacturing, STRATEC can ensure
silicon precision in plastics and high reproducibility.
"We are delighted to be partnering with STRATEC to fabricate our
microfluidic chip. This chip is the essential element of our
label-free technology to enable an efficient and fully-automated
patient sample processing", said Bob Englert, Chief Executive
Officer at Vortex Biosciences. "The transfer from a variable
research-level polymer prototype to a robust and reproducible
plastic commercial chip is a key part of a successful transfer of
technology to the market. This ultimately enables CTCs to be more
widely used in cancer research and become part of the standard of
care", said Elodie Sollier, Chief Scientific Officer and co-founder
at Vortex Biosciences.
"Bringing the Vortex chip into mass-manufacturing was a very
exciting project for us. Vortex is inspiring both in its benefit to
the constantly maturing liquid biopsy market, as well as in their
balance of being science-driven but focused on commercialization.
It is exactly with companies like Vortex where we see our big
strength in actively participating in the transformation process of
a new technology from a lab idea, or early prototypes to an actual
medical product, eventually fit for the IVD market", says
Maximilian Pitzek, Project Manager at STRATEC Consumables.
About Vortex BioSciences
Vortex Biosciences is a cancer research and diagnostics company
that integrates cancer biology, microfluidic engineering and
informatics to develop tools for isolating and characterizing
circulating tumor cells. The Vortex VTX-1 instrument harvests
intact circulating tumor cells from whole blood samples for use in
downstream research and potentially clinical applications such as
patient stratification in clinical trials, monitoring disease
progression and drug treatment effectiveness. With a mission to
enable noninvasive diagnosis of cancer and real-time monitoring
throughout a patient's treatment, Vortex is at the forefront of
accelerating cancer research and improving patient outcomes. Vortex
is a core subsidiary of NetScientific plc, a transatlantic
healthcare technology group with an investment strategy focused on
sourcing, funding and commercializing technologies that
significantly improve the health and well-being of people with
chronic diseases.
For more information, visit www.vortexbiosciences.com.
About STRATEC
STRATEC Biomedical AG (www.stratec.com) designs and manufactures
fully automated analyzer systems for its partners in the fields of
clinical diagnostics and biotechnology. Furthermore, the company
offers sample preparation solutions, integrated laboratory
software, and complex consumables for diagnostic and medical
applications. STRATEC covers the entire value chain - from
development to design and production through to quality
assurance.
The partners market the systems, software and consumables, in
general together with their own reagents, as system solutions to
laboratories, blood banks, and research institutes around the
world. STRATEC develops its products on the basis of its own
patented technologies.
For more information please visit
www.stratec.com/solutions/consumables
Vortex BioSciences Contact:
Bob Englert, CEO
Vortex Biosciences Inc
bob@vortexbiosciences.com
STRATEC Consumables Contact:
Ricarda Pichler
STRATEC Consumables GmbH
+ 43 6248 880 8919
r.pichler@stratec.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAFDDFIFFASEIS
(END) Dow Jones Newswires
November 01, 2018 03:00 ET (07:00 GMT)
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024
